Knight Therapeutics (KHTRF) 6.4000 $KHTRF
Knight and Ember Expand Distribution Partnership
GlobeNewswire - Wed Jul 06, 7:08AM CDT
Knight Therapeutics Inc. (TSX:GUD) ("Knight"
, a leading Canadian specialty pharmaceutical company, and Ember Therapeutics, Inc. (OTCQB:EMBT) ("Ember", a New York-based biotech company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced an expansion of their exclusive distribution agreement signed in August 2015. Pursuant to the amendment, Knight's territorial rights to Ember's Bone Morphogenetic Protein-7 ("BMP-7" pipeline, which originally included Canada, Israel, Russia and sub-Saharan Africa, have been expanded to include Romania and the Caribbean. Additionally, Knight has acquired the exclusive distribution rights for two diversified products recently acquired by Ember: Migralex(TM), a commercially-available over-the-counter medication for treating pain, and ICX-RHY/Vavelta(R), a development stage regenerative medicine asset, in all of the above-mentioned territories.
GUD.TO: 8.28 (+0.20)
Knight Therapeutics Inc. Announces Election of Directors
Marketwire Canada - Thu Jun 16, 5:01PM CDT
MONTREAL, QUEBEC--(Marketwired - Jun 16, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company" announced today that each director nominee listed in the Management Information Circular dated May 13, 2016 was elected as Director of the Company during the Annual Meeting of the Shareholders held in Montréal, Québec.
GUD.TO: 8.28 (+0.20)
Long Zone Holdings Announces Acquisition of Knight Therapeutics Inc. Common Shares
Marketwired - Thu Jun 02, 5:31PM CDT
MONTREAL, QUEBEC--(Marketwired - Jun 2, 2016) - Long Zone Holdings Inc. ("the Corporation" announced that pursuant to a previously announced prospectus offering ("the Offering" by Knight Therapeutics Inc. ("Knight", it has today acquired ownership of 45,000 common shares of Knight ("the Acquired Shares" representing approximately 0.03% of the outstanding common shares of Knight. The Acquired Shares were acquired at a price of $8.00 per common share for an aggregate consideration of $360,000.
Knight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City
Marketwired - Tue May 31, 7:01AM CDT
MONTREAL, QUEBEC--(Marketwired - May 31, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight", a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President and CEO, is scheduled to present at the National Bank Financial Quebec Conference on Wednesday, June 1, 2016 at 2:00 pm ET at the Hotel Le Crystal in Montreal, while Jeffrey Kadanoff, CFO, is scheduled to present a corporate update at the Jefferies Healthcare Conference on Thursday, June 9, 2016 at 9:30 am ET at the Grand Hyatt New York. A copy of the Jefferies Healthcare Conference presentation will be available at www.gud-knight.com.
GUD.TO: 8.28 (+0.20)
Knight Reports First Quarter 2016 Results
Marketwire Canada - Tue May 10, 5:01AM CDT
MONTREAL, CANADA--(Marketwired - May 10, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company", a leading Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2016. In thousands of Canadian dollars except for share and per share amounts.
GUD.TO: 8.28 (+0.20)
Knight Finds EMPAthetic Partner for Neuragen(R) in the Middle East
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly-owned subsidiaries ("Knight", announced today that it has entered into an exclusive distribution agreement with EMPA Healthcare LLC ("EMPA" to commercialize Neuragen(R), a topical natural health product used to relieve the symptoms of peripheral nerve pain, in the United Arab Emirates and Kuwait. EMPA will also have non-exclusive distribution rights in the other Gulf Cooperation Council ("GCC" countries. Knight may extend exclusivity on a country-by-country basis should certain minimum sales targets be met in each GCC country. Knight sold the rights to Neuragen(R) in the U.S. in June 2015 and retains the rights for all other territories.
GUD.TO: 8.28 (+0.20)
Knight Receives NOD from Health Canada for ATryn(R)
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight", a leading Canadian specialty pharmaceutical company, today announced that it has received a Notice of Deficiency ("NOD" for its ATryn(R) New Drug Submission.
GUD.TO: 8.28 (+0.20)
Knight Blooms at Healthcare Investor Conference in Toronto
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight", a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan Ross Goodman, President and CEO, and Mr. Jeffrey Kadanoff, CFO, are scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2016 at 1:30 pm ET at the Sheraton Centre Toronto Hotel. A copy of the presentation will be available at www.gud-knight.com.
GUD.TO: 8.28 (+0.20)
Knight Therapeutics CFO Jeffrey Kadanoff at Cercle Finance et Placement du Québec on April 19
CNW Group - Wed Apr 13, 9:30AM CDT
Members of the media are invited to a presentation by Jeffrey Kadanoff, Chief Financial Officer of Knight Therapeutics, who will be the guest speaker at Le Cercle finance et placement du Québec's next luncheon conference, to be held on Tuesday, April 19. Please note that the presentation will be in French.
Knight Reports Fourth Quarter and Year-Ended December 31, 2015 Results
Marketwired - Thu Mar 24, 5:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company", a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year-ended December 31, 2015.
GUD.TO: 8.28 (+0.20)
Knight Receives Dividend From Medison
Marketwired - Wed Mar 23, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly-owned subsidiaries ("Knight", announced today receipt of a NIS 7.1 million ($2.4 million) dividend from Medison Biotech (1995) Ltd. ("Medison". Knight owns 28.3% of Medison, Israels 4th largest specialty pharma company ranked by revenue.
GUD.TO: 8.28 (+0.20)
Knight and Ember Expand Distribution Partnership
GlobeNewswire - Wed Jul 06, 7:08AM CDT
Knight Therapeutics Inc. (TSX:GUD) ("Knight"
, a leading Canadian specialty pharmaceutical company, and Ember Therapeutics, Inc. (OTCQB:EMBT) ("Ember", a New York-based biotech company developing targeted therapies for osteoarthritis, kidney fibrosis, and other regenerative medicines, today announced an expansion of their exclusive distribution agreement signed in August 2015. Pursuant to the amendment, Knight's territorial rights to Ember's Bone Morphogenetic Protein-7 ("BMP-7" pipeline, which originally included Canada, Israel, Russia and sub-Saharan Africa, have been expanded to include Romania and the Caribbean. Additionally, Knight has acquired the exclusive distribution rights for two diversified products recently acquired by Ember: Migralex(TM), a commercially-available over-the-counter medication for treating pain, and ICX-RHY/Vavelta(R), a development stage regenerative medicine asset, in all of the above-mentioned territories. GUD.TO: 8.28 (+0.20)
Knight Therapeutics Inc. Announces Election of Directors
Marketwire Canada - Thu Jun 16, 5:01PM CDT
MONTREAL, QUEBEC--(Marketwired - Jun 16, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"
announced today that each director nominee listed in the Management Information Circular dated May 13, 2016 was elected as Director of the Company during the Annual Meeting of the Shareholders held in Montréal, Québec. GUD.TO: 8.28 (+0.20)
Long Zone Holdings Announces Acquisition of Knight Therapeutics Inc. Common Shares
Marketwired - Thu Jun 02, 5:31PM CDT
MONTREAL, QUEBEC--(Marketwired - Jun 2, 2016) - Long Zone Holdings Inc. ("the Corporation"
announced that pursuant to a previously announced prospectus offering ("the Offering" by Knight Therapeutics Inc. ("Knight", it has today acquired ownership of 45,000 common shares of Knight ("the Acquired Shares" representing approximately 0.03% of the outstanding common shares of Knight. The Acquired Shares were acquired at a price of $8.00 per common share for an aggregate consideration of $360,000. Knight to Present at Both the National Bank Financial Quebec Conference in Montreal and the Jefferies Healthcare Conference in New York City
Marketwired - Tue May 31, 7:01AM CDT
MONTREAL, QUEBEC--(Marketwired - May 31, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight"
, a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President and CEO, is scheduled to present at the National Bank Financial Quebec Conference on Wednesday, June 1, 2016 at 2:00 pm ET at the Hotel Le Crystal in Montreal, while Jeffrey Kadanoff, CFO, is scheduled to present a corporate update at the Jefferies Healthcare Conference on Thursday, June 9, 2016 at 9:30 am ET at the Grand Hyatt New York. A copy of the Jefferies Healthcare Conference presentation will be available at www.gud-knight.com. GUD.TO: 8.28 (+0.20)
Knight Reports First Quarter 2016 Results
Marketwire Canada - Tue May 10, 5:01AM CDT
MONTREAL, CANADA--(Marketwired - May 10, 2016) - Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2016. In thousands of Canadian dollars except for share and per share amounts. GUD.TO: 8.28 (+0.20)
Knight Finds EMPAthetic Partner for Neuragen(R) in the Middle East
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly-owned subsidiaries ("Knight"
, announced today that it has entered into an exclusive distribution agreement with EMPA Healthcare LLC ("EMPA" to commercialize Neuragen(R), a topical natural health product used to relieve the symptoms of peripheral nerve pain, in the United Arab Emirates and Kuwait. EMPA will also have non-exclusive distribution rights in the other Gulf Cooperation Council ("GCC" countries. Knight may extend exclusivity on a country-by-country basis should certain minimum sales targets be met in each GCC country. Knight sold the rights to Neuragen(R) in the U.S. in June 2015 and retains the rights for all other territories. GUD.TO: 8.28 (+0.20)
Knight Receives NOD from Health Canada for ATryn(R)
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"
, a leading Canadian specialty pharmaceutical company, today announced that it has received a Notice of Deficiency ("NOD" for its ATryn(R) New Drug Submission. GUD.TO: 8.28 (+0.20)
Knight Blooms at Healthcare Investor Conference in Toronto
Marketwired - Mon Apr 25, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"
, a leading Canadian specialty pharmaceutical company, announced today that Mr. Jonathan Ross Goodman, President and CEO, and Mr. Jeffrey Kadanoff, CFO, are scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2016 at 1:30 pm ET at the Sheraton Centre Toronto Hotel. A copy of the presentation will be available at www.gud-knight.com. GUD.TO: 8.28 (+0.20)
Knight Therapeutics CFO Jeffrey Kadanoff at Cercle Finance et Placement du Québec on April 19
CNW Group - Wed Apr 13, 9:30AM CDT
Members of the media are invited to a presentation by Jeffrey Kadanoff, Chief Financial Officer of Knight Therapeutics, who will be the guest speaker at Le Cercle finance et placement du Québec's next luncheon conference, to be held on Tuesday, April 19. Please note that the presentation will be in French.
Knight Reports Fourth Quarter and Year-Ended December 31, 2015 Results
Marketwired - Thu Mar 24, 5:01AM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"
, a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year-ended December 31, 2015. GUD.TO: 8.28 (+0.20)
Knight Receives Dividend From Medison
Marketwired - Wed Mar 23, 7:02AM CDT
Knight Therapeutics Inc. (TSX: GUD), through one of its wholly-owned subsidiaries ("Knight"
, announced today receipt of a NIS 7.1 million ($2.4 million) dividend from Medison Biotech (1995) Ltd. ("Medison". Knight owns 28.3% of Medison, Israels 4th largest specialty pharma company ranked by revenue. GUD.TO: 8.28 (+0.20)
